Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-31

Clinical Trial Update: Aliskiren Effect on Aortic Plaque Progression [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluated aliskiren for slowing aortic plaque progression in atherosclerosis. The study was terminated and results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tekturna (aliskiren)

Snippet

Sponsor: Ohio State University | Conditions: Atherosclerosis | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2012-12-31